Jeffrey Leiden - Vertex Pharmaceuticals Insider

Vertex Pharmaceuticals Incorporated -- USA Stock  

USD 154.76  0.29  0.19%

Chairman of the Board and Presidentident, CEO

Dr. Jeffrey M. Leiden, M.D., Ph.D., is Chairman of the Board, President, Chief Executive Officer of Vertex Pharmaceuticals Incorporated. Dr. Leiden is our Chairman, Chief Executive Officer and President. He has held the positions of Chief Executive Officer and President since February 2012 after joining us as CEO Designee in December 2011. He was a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences VC firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden is a senior advisor to Clarus Ventures. Dr. Leiden serves as a director of Quest Diagnostics Inc., a medical diagnostics company, and Massachusetts Mutual Life Insurance Company, an insurance company. Dr. Leiden was a director and the nonexecutive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012
Age: 60  Chairman Since 2012  Ph.D    
617-341-6100  www.vrtx.com
Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.

Jeffrey Leiden Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 7.67 % which means that it generated profit of $7.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 17.72 % meaning that it created $17.72 on every $100 dollars invested by stockholders.
The company currently holds 568.54 M in liabilities with Debt to Equity (D/E) ratio of 30.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals Incorporated has Current Ratio of 3.42 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 5 records

CHAIRMAN Since

Miles WhiteAbbott Laboratories
1999
Paul BisaroAllergan plc
2016
Norman SchwartzBio Rad Laboratories Inc
2012
Roger KimmelEndo International plc
2007
Dennis GillingsQuintiles IMS Holdings Inc
2016

Entity Summary

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases. Vertex Pharmaceuticals Incorporated (VRTX) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 1,950 people. Vertex Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Fund Screener Now
   

Fund Screener

Find activelly-traded funds from around the world traded on over 30 global exchanges
Hide  View All  Next  Launch Fund Screener
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Vertex Pharmaceuticals Incorporated to your portfolio

Top Management

Vertex Pharmaceuticals Leadership Team
Paul Silva, President
William Young, Director, MBA
David Altshuler, Director
Jeffrey Chodakewitz, President
Elaine Ullian, Director
Michael Parini, President
Alan Garber, Director, Ph.D
Amit Sachdev, President
Joshua Boger, Chairman
David Greenway, Director
Bruce Sachs, Director, MBA
Margaret McGlynn, Director, MBA
Michael Partridge, President
Yuchun Lee, Director, MBA
Sangeeta Bhatia, Director, Ph.D
Stuart Arbuckle, EVP
Thomas Graney, President, MBA
Terrence Kearney, Director, MBA
Ian Smith, President
Jeffrey Leiden, Chairman, Ph.D

Stock Performance

Vertex Pharmaceuticals Performance Indicators